STOCK TITAN

Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

The Center for Disease Analysis Foundation (CDAF) has announced $782,000 in funding for its third round of Relink program grantees, benefiting six healthcare institutions across different states. The program, funded by an $8 million grant from Gilead Sciences (GILD), aims to reconnect diagnosed but untreated Hepatitis C (HCV) and Hepatitis B (HBV) patients to care.

This initiative represents the largest global effort to support the World Health Organization's 2030 Viral Hepatitis Elimination goals in the United States. Despite progress in the last decade, patient retention remains challenging due to fragmented management systems. The program focuses on implementing culturally appropriate and innovative programs to improve relinkage to care.

The fourth and final round of proposals will open in September 2025, with priority given to state health agencies and their partners.

Il Center for Disease Analysis Foundation (CDAF) ha annunciato un finanziamento di 782.000 dollari per il suo terzo round di beneficiari del programma Relink, a beneficio di sei istituzioni sanitarie in diversi stati. Il programma, finanziato da una borsa di 8 milioni di dollari da Gilead Sciences (GILD), mira a riconnettere i pazienti diagnosticati ma non trattati per l'epatite C (HCV) e l'epatite B (HBV) alle cure.

Questa iniziativa rappresenta il più grande sforzo globale per sostenere gli obiettivi di eliminazione delle epatiti virali 2030 dell'Organizzazione Mondiale della Sanità negli Stati Uniti. Nonostante i progressi dell'ultimo decennio, la retention dei pazienti rimane una sfida a causa dei sistemi di gestione frammentati. Il programma si concentra sull'implementazione di programmi culturalmente appropriati e innovativi per migliorare il reinserimento nelle cure.

Il quarto e ultimo round di proposte aprirà a settembre 2025, con priorità data alle agenzie sanitarie statali e ai loro partner.

El Center for Disease Analysis Foundation (CDAF) ha anunciado una financiación de 782,000 dólares para su tercera ronda de beneficiarios del programa Relink, beneficiando a seis instituciones de salud en diferentes estados. El programa, financiado por una subvención de 8 millones de dólares de Gilead Sciences (GILD), tiene como objetivo reconectar a los pacientes diagnosticados pero no tratados de Hepatitis C (HCV) y Hepatitis B (HBV) con la atención médica.

Esta iniciativa representa el mayor esfuerzo global para apoyar los objetivos de eliminación de Hepatitis Viral 2030 de la Organización Mundial de la Salud en los Estados Unidos. A pesar de los avances en la última década, la retención de pacientes sigue siendo un desafío debido a los sistemas de gestión fragmentados. El programa se centra en implementar programas culturalmente apropiados e innovadores para mejorar la reconexión con la atención.

La cuarta y última ronda de propuestas se abrirá en septiembre de 2025, dando prioridad a las agencias de salud estatales y sus socios.

질병 분석 센터 재단 (CDAF)은 Relink 프로그램의 세 번째 지원자에게 782,000달러의 자금을 발표했습니다. 이 프로그램은 다양한 주의 여섯 개 의료 기관에 혜택을 주고 있습니다. 이 프로그램은 Gilead Sciences (GILD)의 800만 달러 보조금으로 자금을 지원받아, 진단되었지만 치료되지 않은 C형 간염 (HCV) 및 B형 간염 (HBV) 환자들을 치료와 다시 연결하는 것을 목표로 합니다.

이 이니셔티브는 미국에서 세계 보건 기구의 2030년 바이러스 간염 제거 목표를 지원하기 위한 가장 큰 글로벌 노력입니다. 지난 10년 동안의 진전에도 불구하고 환자 유지율은 단편화된 관리 시스템으로 인해 여전히 도전 과제가 되고 있습니다. 이 프로그램은 치료와의 재연결을 개선하기 위해 문화적으로 적절하고 혁신적인 프로그램을 구현하는 데 중점을 두고 있습니다.

네 번째이자 마지막 제안 라운드는 2025년 9월에 열리며, 주 보건 기관과 그 파트너에게 우선권이 주어질 것입니다.

Le Center for Disease Analysis Foundation (CDAF) a annoncé un financement de 782 000 dollars pour son troisième tour de bénéficiaires du programme Relink, bénéficiant à six institutions de santé dans différents États. Le programme, financé par une subvention de 8 millions de dollars de Gilead Sciences (GILD), vise à reconnecter les patients diagnostiqués mais non traités pour l'hépatite C (HCV) et l'hépatite B (HBV) aux soins.

Cette initiative représente le plus grand effort mondial pour soutenir les objectifs d'élimination de l'hépatite virale 2030 de l'Organisation mondiale de la santé aux États-Unis. Malgré les progrès réalisés au cours de la dernière décennie, la rétention des patients reste un défi en raison de systèmes de gestion fragmentés. Le programme se concentre sur la mise en œuvre de programmes culturellement appropriés et innovants pour améliorer le lien avec les soins.

Le quatrième et dernier tour de propositions ouvrira en septembre 2025, avec une priorité accordée aux agences de santé des États et à leurs partenaires.

Die Center for Disease Analysis Foundation (CDAF) hat eine Finanzierung von 782.000 Dollar für die dritte Runde der Begünstigten des Relink-Programms angekündigt, von der sechs Gesundheitseinrichtungen in verschiedenen Bundesstaaten profitieren. Das Programm, das durch einen 8-Millionen-Dollar-Zuschuss von Gilead Sciences (GILD) finanziert wird, zielt darauf ab, diagnostizierte, aber unbehandelte Hepatitis C (HCV) und Hepatitis B (HBV) Patienten wieder in die Versorgung zu bringen.

Diese Initiative stellt den größten globalen Versuch dar, die Ziele der Weltgesundheitsorganisation zur Eliminierung von Virushepatitis bis 2030 in den Vereinigten Staaten zu unterstützen. Trotz der Fortschritte im letzten Jahrzehnt bleibt die Patientenbindung aufgrund fragmentierter Managementsysteme eine Herausforderung. Das Programm konzentriert sich auf die Umsetzung kulturell angemessener und innovativer Programme zur Verbesserung der Wiederanbindung an die Versorgung.

Die vierte und letzte Runde der Vorschläge wird im September 2025 eröffnet, wobei den staatlichen Gesundheitsbehörden und ihren Partnern Vorrang eingeräumt wird.

Positive
  • GILD demonstrates commitment to hepatitis treatment market with $8 million grant funding
  • Program strengthens GILD's market position in hepatitis treatment sector
Negative
  • None.

LAFAYETTE, Colo.--(BUSINESS WIRE)-- Building on the progress of the first two rounds, the Center for Disease Analysis Foundation (CDAF) Relink program is pleased to announce seven hundred and eighty-two thousand dollars in funding for its third round of grantees. The following six organizations are beneficiaries:

Organization

Organization Type

State

Bluestone Health Association Inc.

Healthcare Institution

WV

Carilion Clinic

Healthcare Institution

VA

Cooperman Barnabas Medical Center

Healthcare Institution

NJ

First Choice Primary Care, Inc.

Healthcare Institution

GA

TruReach Inc

Healthcare Institution

PA

University of Kentucky Research Foundation

Healthcare Institution

KY

The CDAF Relink program is in its second year of operation. Funded by an eight-million-dollar grant from the Gilead Sciences (Nasdaq: GILD) Relink program, it is currently the largest global effort to reconnect diagnosed but untreated Hepatitis C (HCV) and Hepatitis B (HBV) infected individuals to care. This is a crucial step toward achieving the World Health Organization’s 2030 Viral Hepatitis Elimination goals in the United States (U.S.). Significant progress has been made toward elimination in the last decade. However, increasing the number of HCV-infected people who complete treatment and are cured, or HBV-infected people who are retained in care remains challenging.

“In the case of HCV, many high-income countries like the U.S. are considered early adopters, that is, they were on the frontlines of diagnosis and treatment for HCV,” noted Homie Razavi, the Managing Director of CDA Foundation. “However, due to fragmented patient management systems, many diagnosed individuals are lost to follow up. It is possible that more than half of the population believed to be diagnosed but untreated may already be receiving care somewhere or have passed away. Additionally, organizational and legal constraints often prevent organizations from fully leveraging patient navigators to engage with the community and link individuals from high-risk groups to appropriate care. However, implementing culturally appropriate and innovative programs which meet patients at their point of need is sure to improve relinkage to care.”

Fundisani Mangena, Chief Operating Officer of First Choice Primary Care, believes the initiative will make a lasting impact on the well-being of the community served by his organization. “This funding supports our mission to improve health outcomes by closing treatment gaps and ensuring patients receive timely, life-changing care,” he stated. “Treatments and medications have come a long way,” said Tuesdae Stainbrook, D.O., MPH, chief investigator of TruReach Inc, another beneficiary. “These funds will help break down barriers that have prevented patients from engaging in care upon diagnosis.”

The call for a fourth and final round of proposals will open in September 2025. Proposals from state health agencies and their partners will be given priority. For more information, please visit https://cdafound.org/relink or contact the CDAF-Relink program at relink@cdafound.org.

About Center for Disease Analysis Foundations

CDA Foundation is a non-profit organization that seeks to help eliminate HBV and HCV globally by 2030 by providing countries across the world with verified epidemiological data, disease burden and economic impact modeling, smart intervention strategies, access to affordable diagnostics and treatments, innovative financing, and knowledge-sharing partnerships to eliminate these deadly infections. It works with more than 110 countries globally and 26 US states on their viral hepatitis elimination programs. CDA Foundation is headquartered in Lafayette.

Homie Razavi

hrazavi@cdafound.org

Source: Center for Disease Analysis Foundation

FAQ

How much funding did GILD provide for the CDAF Relink program?

Gilead Sciences (GILD) provided an $8 million grant to fund the CDAF Relink program.

What is the total amount awarded in the third round of CDAF Relink grants?

The third round of CDAF Relink grants awarded $782,000 in total funding.

How many healthcare institutions received grants in the third round of CDAF Relink program?

Six healthcare institutions across different states received grants in the third round.

When will the final round of CDAF Relink program proposals open?

The fourth and final round of proposals will open in September 2025.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

139.32B
1.24B
0.11%
89.78%
1.81%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY